Search company, investor...

NiKang Therapeutics

Founded Year



Series C | Alive

Total Raised


Last Raised

$200M | 2 yrs ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+30 points in the past 30 days

About NiKang Therapeutics

NiKang Therapeutics is an early stage biotech company focused on discovering and developing small molecule oncology medicines to help patients with unmet medical needs.

Headquarters Location

200 Power Mill Road BLDG E500

Wilmington, Delaware, 19803,

United States


Missing: NiKang Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: NiKang Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing NiKang Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned NiKang Therapeutics in 1 CB Insights research brief, most recently on Aug 5, 2021.

Expert Collections containing NiKang Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NiKang Therapeutics is included in 2 Expert Collections, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

NiKang Therapeutics Patents

NiKang Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Transcription factors
  • Clusters of differentiation
  • Proteins
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Clusters of differentiation, Proteins, Experimental cancer drugs, Human proteins


Application Date


Grant Date



Related Topics

Transcription factors, Clusters of differentiation, Proteins, Experimental cancer drugs, Human proteins



Latest NiKang Therapeutics News

Hansoh wins greater China rights to oncology drug from Nikang in $218M deal

May 10, 2022

May 10, 2022 Hansoh Pharmaceutical Group Co. Ltd. has acquired greater China rights to oncology candidate NKT-2152 from Nikang Therapeutics Inc. in a deal worth up to $218 million. Jiangsu, China-based Hansoh picked up exclusive rights to develop and commercialize the candidate in mainland China, Hong Kong, Macau and Taiwan. In turn, Nikang is eligible to receive $15 million up-front cash payment, as well as up to $203 million in potential development, regulatory and sales-based milestone payments, and tiered royalties.

NiKang Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

NiKang Therapeutics Rank

NiKang Therapeutics Frequently Asked Questions (FAQ)

  • When was NiKang Therapeutics founded?

    NiKang Therapeutics was founded in 2017.

  • Where is NiKang Therapeutics's headquarters?

    NiKang Therapeutics's headquarters is located at 200 Power Mill Road, Wilmington.

  • What is NiKang Therapeutics's latest funding round?

    NiKang Therapeutics's latest funding round is Series C.

  • How much did NiKang Therapeutics raise?

    NiKang Therapeutics raised a total of $250M.

  • Who are the investors of NiKang Therapeutics?

    Investors of NiKang Therapeutics include Matrix Partners China, Casdin Capital, HBM Healthcare Investments, Lilly Asia Ventures, CBC Group and 19 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.